{"title":"A Comparison of Provider Delays In Newly Diagnosed Breast Cancer Patients At Two Public Hospitals In South Africa","authors":"Thegesha Naidoo, Modise Zacharia Koto, Branny Mthelebofu, Matlou Mabitsela","doi":"10.12691/jcrt-11-1-2","DOIUrl":"https://doi.org/10.12691/jcrt-11-1-2","url":null,"abstract":"","PeriodicalId":9541,"journal":{"name":"Cancer Research and Treatment : Official Journal of Korean Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135109814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jonathan D. Rockoff, Akhil A. Saji, Jonathan Kroop, M. Choudhury, S. Konno
{"title":"Possible Anticancer Effect of Bioactive Extract Isolated from Agrocybe Chaxingu on Human Bladder Cancer Cells","authors":"Jonathan D. Rockoff, Akhil A. Saji, Jonathan Kroop, M. Choudhury, S. Konno","doi":"10.12691/jcrt-11-1-1","DOIUrl":"https://doi.org/10.12691/jcrt-11-1-1","url":null,"abstract":"","PeriodicalId":9541,"journal":{"name":"Cancer Research and Treatment : Official Journal of Korean Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90432957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Chemoresistance is one of the major challenges for the acute myeloid leukemia (AML) treatment. Venetoclax (ABT-199), a selective small molecule BCL-2 inhibitor, is being clinically vetted and is an effective therapy for some B-cell lymphomas, yet many patients who initially respond to ABT-199 develop resistance. Thus, enhancing the sensitivity of resistant cells to chemotherapy is a great interest to clinical trial. Method: The resistant cell lines were generated by culturing in the medium containing ABT-199. CCK8 analysis was used to detect the cell viability. Flowcytometric analysis with Annexin-V/PI was used to test the apoptosis. CRISPR/Cas9 by lentivirus delivering well-validated shRNAs in pLKO.1 vector was used to knockout the expression of MTF1. Western blot with the antibodies was used to determine the expression of the molecules. Clonogenic growth assay was used to determine the growth of parental and DTEP cells. Results: Here we report that resistance to the BCL-2 targeting drug ABT-199 in AML cell lines evolves from outgrowth of persister clones harbor BCL2. Furthermore, persister status is generated via adaptive super-enhancer remodeling that reprograms transcription and offers opportunities for overcoming ABT-199 resistance. Notably, pharmacogenomic screens revealed that persisters are vulnerable to inhibition of metal regulatory transcription factor 1 (MTF1), which is essential for the transcriptional reprogramming that drives and sustains ABT-199 resistance. Conclusion: LOR-253, which is a MTF1-targeting agent, add novel insights to overcome ABT-199-resistance in B-cell lymphomas.
{"title":"LOR-253 Overcomes Resistance to ABT-199 by Targeting MTF1 in AML","authors":"Chenchen Wang, Li-Bin Han, Ming-Ming Ding, Xiaoxiao Wang, Yun-long Hou","doi":"10.12691/jcrt-9-2-2","DOIUrl":"https://doi.org/10.12691/jcrt-9-2-2","url":null,"abstract":"Introduction: Chemoresistance is one of the major challenges for the acute myeloid leukemia (AML) treatment. Venetoclax (ABT-199), a selective small molecule BCL-2 inhibitor, is being clinically vetted and is an effective therapy for some B-cell lymphomas, yet many patients who initially respond to ABT-199 develop resistance. Thus, enhancing the sensitivity of resistant cells to chemotherapy is a great interest to clinical trial. Method: The resistant cell lines were generated by culturing in the medium containing ABT-199. CCK8 analysis was used to detect the cell viability. Flowcytometric analysis with Annexin-V/PI was used to test the apoptosis. CRISPR/Cas9 by lentivirus delivering well-validated shRNAs in pLKO.1 vector was used to knockout the expression of MTF1. Western blot with the antibodies was used to determine the expression of the molecules. Clonogenic growth assay was used to determine the growth of parental and DTEP cells. Results: Here we report that resistance to the BCL-2 targeting drug ABT-199 in AML cell lines evolves from outgrowth of persister clones harbor BCL2. Furthermore, persister status is generated via adaptive super-enhancer remodeling that reprograms transcription and offers opportunities for overcoming ABT-199 resistance. Notably, pharmacogenomic screens revealed that persisters are vulnerable to inhibition of metal regulatory transcription factor 1 (MTF1), which is essential for the transcriptional reprogramming that drives and sustains ABT-199 resistance. Conclusion: LOR-253, which is a MTF1-targeting agent, add novel insights to overcome ABT-199-resistance in B-cell lymphomas.","PeriodicalId":9541,"journal":{"name":"Cancer Research and Treatment : Official Journal of Korean Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72722706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-31DOI: 10.1201/9780429026638-27
T. Delaney, D. Harmon, K. Sikora, F. Hornicek
{"title":"Soft Tissue Sarcomas","authors":"T. Delaney, D. Harmon, K. Sikora, F. Hornicek","doi":"10.1201/9780429026638-27","DOIUrl":"https://doi.org/10.1201/9780429026638-27","url":null,"abstract":"","PeriodicalId":9541,"journal":{"name":"Cancer Research and Treatment : Official Journal of Korean Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81615568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-31DOI: 10.1201/9780429026638-23
M. Seckl
{"title":"Gestational Trophoblastic Neoplasia","authors":"M. Seckl","doi":"10.1201/9780429026638-23","DOIUrl":"https://doi.org/10.1201/9780429026638-23","url":null,"abstract":"","PeriodicalId":9541,"journal":{"name":"Cancer Research and Treatment : Official Journal of Korean Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81824624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-31DOI: 10.1201/9780429026638-22
S. Ghaem-Maghami, K. Lathouras
{"title":"Carcinoma of the Vagina and Vulva","authors":"S. Ghaem-Maghami, K. Lathouras","doi":"10.1201/9780429026638-22","DOIUrl":"https://doi.org/10.1201/9780429026638-22","url":null,"abstract":"","PeriodicalId":9541,"journal":{"name":"Cancer Research and Treatment : Official Journal of Korean Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80439580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Breast Cancer","authors":"A. Case, G. Edwards, C. Pembroke","doi":"10.1201/9780429026638-6","DOIUrl":"https://doi.org/10.1201/9780429026638-6","url":null,"abstract":"","PeriodicalId":9541,"journal":{"name":"Cancer Research and Treatment : Official Journal of Korean Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91522909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lung Cancer","authors":"Michael Flynn, N. Yousaf","doi":"10.1201/9780429026638-7","DOIUrl":"https://doi.org/10.1201/9780429026638-7","url":null,"abstract":"","PeriodicalId":9541,"journal":{"name":"Cancer Research and Treatment : Official Journal of Korean Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86793274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Neuroendocrine tumours (NETs) consist of a heterogeneous group of neoplasms arising from avarietyof neuroendocrine cell types. According to criteria of the European legislation, some may be orphan indications. However, epidemiologic data on specific sub-types of NETs are scarce. This studyaimed at assessing the prevalence of gastroenteropancreatic (GEP) and lung NETs in the European Union. Methods: Systematic literature reviews were conducted using Medline and Embase bibliographical databases. Search strategies combined the following concepts, using MeSH and Emtree terms: Disease of interest, epidemiologic? data (incidence or prevalence) and countries of interest. The search period covered 1st Jan 2010 to 15 Feb 2016, inclusively. Pragmatic searches of web sources and conference proceedings were also conducted. Using data identified in the search, prevalence rates were estimated using the relationship between prevalence (P), incidence (I), and disease duration (D), where applicable. Size of the EU population as of 1 st January 2015 was used to estimate number of patients with GEPand lung NETs. As incidences rates and survival of patients varyacross countries and settings, sensitivityanalyses were also performed. Results: A total of 87 and 23 sources were identified through the literature search and pragmatic search, respectively for GEP-NETs and lung NETs. Following in-depth review, 8 and 6 data sources were retained forepidemiologic data extraction on GEP and lung NETs, respectively.Considering, the highest estimated prevalence rates of GEP-NETs and lung NETs (3.8 and 1.9
{"title":"Endocrine and Neuroendocrine Tumors","authors":"A. Grossman, Márta Korbonitis, P. Plowman","doi":"10.1201/b17751-6","DOIUrl":"https://doi.org/10.1201/b17751-6","url":null,"abstract":"Background: Neuroendocrine tumours (NETs) consist of a heterogeneous group of neoplasms arising from avarietyof neuroendocrine cell types. According to criteria of the European legislation, some may be orphan indications. However, epidemiologic data on specific sub-types of NETs are scarce. This studyaimed at assessing the prevalence of gastroenteropancreatic (GEP) and lung NETs in the European Union. Methods: Systematic literature reviews were conducted using Medline and Embase bibliographical databases. Search strategies combined the following concepts, using MeSH and Emtree terms: Disease of interest, epidemiologic? data (incidence or prevalence) and countries of interest. The search period covered 1st Jan 2010 to 15 Feb 2016, inclusively. Pragmatic searches of web sources and conference proceedings were also conducted. Using data identified in the search, prevalence rates were estimated using the relationship between prevalence (P), incidence (I), and disease duration (D), where applicable. Size of the EU population as of 1 st January 2015 was used to estimate number of patients with GEPand lung NETs. As incidences rates and survival of patients varyacross countries and settings, sensitivityanalyses were also performed. Results: A total of 87 and 23 sources were identified through the literature search and pragmatic search, respectively for GEP-NETs and lung NETs. Following in-depth review, 8 and 6 data sources were retained forepidemiologic data extraction on GEP and lung NETs, respectively.Considering, the highest estimated prevalence rates of GEP-NETs and lung NETs (3.8 and 1.9","PeriodicalId":9541,"journal":{"name":"Cancer Research and Treatment : Official Journal of Korean Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90268249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Central Nervous System","authors":"S. Short, L. Murray","doi":"10.1201/9780429026638-1","DOIUrl":"https://doi.org/10.1201/9780429026638-1","url":null,"abstract":"","PeriodicalId":9541,"journal":{"name":"Cancer Research and Treatment : Official Journal of Korean Cancer Association","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88991721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：